CEL-SCI (CVM) Competitors $9.45 +1.27 (+15.53%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$9.29 -0.16 (-1.69%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVM vs. LFVN, IMAB, BDTX, BIOA, PBYI, NVCT, CCCC, ACOG, ENTA, and MOLNShould you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Lifevantage (LFVN), I-Mab (IMAB), Black Diamond Therapeutics (BDTX), BioAge Labs (BIOA), Puma Biotechnology (PBYI), Nuvectis Pharma (NVCT), C4 Therapeutics (CCCC), Alpha Cognition (ACOG), Enanta Pharmaceuticals (ENTA), and Molecular Partners (MOLN). These companies are all part of the "pharmaceutical products" industry. CEL-SCI vs. Its Competitors Lifevantage I-Mab Black Diamond Therapeutics BioAge Labs Puma Biotechnology Nuvectis Pharma C4 Therapeutics Alpha Cognition Enanta Pharmaceuticals Molecular Partners Lifevantage (NASDAQ:LFVN) and CEL-SCI (NYSE:CVM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings. Does the media prefer LFVN or CVM? In the previous week, CEL-SCI had 5 more articles in the media than Lifevantage. MarketBeat recorded 5 mentions for CEL-SCI and 0 mentions for Lifevantage. CEL-SCI's average media sentiment score of 1.08 beat Lifevantage's score of 0.00 indicating that CEL-SCI is being referred to more favorably in the news media. Company Overall Sentiment Lifevantage Neutral CEL-SCI Positive Do insiders and institutionals believe in LFVN or CVM? 35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 12.1% of CEL-SCI shares are owned by institutional investors. 20.7% of Lifevantage shares are owned by insiders. Comparatively, 9.9% of CEL-SCI shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is LFVN or CVM more profitable? Lifevantage has a net margin of 4.12% compared to CEL-SCI's net margin of 0.00%. Lifevantage's return on equity of 34.67% beat CEL-SCI's return on equity.Company Net Margins Return on Equity Return on Assets Lifevantage4.12% 34.67% 15.24% CEL-SCI N/A -238.05%-104.65% Do analysts prefer LFVN or CVM? Lifevantage presently has a consensus price target of $30.50, indicating a potential upside of 142.45%. Given Lifevantage's stronger consensus rating and higher probable upside, research analysts clearly believe Lifevantage is more favorable than CEL-SCI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifevantage 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00CEL-SCI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, LFVN or CVM? Lifevantage has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, CEL-SCI has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Which has higher valuation and earnings, LFVN or CVM? Lifevantage has higher revenue and earnings than CEL-SCI. CEL-SCI is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifevantage$200.16M0.79$2.94M$0.6918.23CEL-SCIN/AN/A-$26.92M-$12.61-0.75 SummaryLifevantage beats CEL-SCI on 13 of the 15 factors compared between the two stocks. Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVM vs. The Competition Export to ExcelMetricCEL-SCIBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$50.28M$267.92M$5.49B$20.65BDividend YieldN/AN/A4.73%3.67%P/E Ratio-19.69N/A28.7829.03Price / SalesN/A327.48372.2066.13Price / CashN/A22.4435.4522.84Price / Book63.0010.418.274.43Net Income-$26.92M-$106.40M$3.25B$994.22M7 Day Performance15.24%-7.85%-3.70%-3.39%1 Month Performance275.00%18.32%4.34%-2.09%1 Year Performance-72.37%6.03%25.90%10.09% CEL-SCI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVMCEL-SCI1.2111 of 5 stars$9.45+15.5%N/A-72.6%$50.28MN/A-19.6943Positive NewsShort Interest ↑LFVNLifevantage3.8043 of 5 stars$13.13-4.2%$30.50+132.3%+55.9%$172.58M$200.16M19.03260IMABI-Mab2.514 of 5 stars$1.87-11.4%$6.00+220.9%+100.0%$172.30MN/A0.00380News CoverageGap UpHigh Trading VolumeBDTXBlack Diamond Therapeutics2.3023 of 5 stars$2.93-1.3%$12.80+336.9%-57.3%$168.88M$70M48.8390Positive NewsUpcoming EarningsGap DownBIOABioAge LabsN/A$4.53-1.9%N/AN/A$165.63MN/A0.00N/APositive NewsPBYIPuma Biotechnology3.6469 of 5 stars$3.34+1.8%$7.00+109.6%-12.3%$162.79M$230.50M4.34200Upcoming EarningsNVCTNuvectis Pharma2.3816 of 5 stars$7.60-2.3%$17.00+123.7%+10.0%$162.55MN/A-6.738News CoverageUpcoming EarningsAnalyst RevisionCCCCC4 Therapeutics2.3831 of 5 stars$2.18-3.5%$12.00+450.5%-68.3%$160.48M$35.58M-1.48150News CoveragePositive NewsACOGAlpha Cognition1.2242 of 5 stars$9.73-2.4%$20.00+105.5%N/A$159.72MN/A-8.11N/APositive NewsENTAEnanta Pharmaceuticals3.7048 of 5 stars$8.03+8.5%$18.50+130.4%-52.0%$158.19M$67.64M-1.77160News CoverageUpcoming EarningsAnalyst RevisionGap UpMOLNMolecular Partners2.172 of 5 stars$3.88+0.3%$12.00+209.3%-55.9%$156.19M$5.65M-2.02180Gap Down Related Companies and Tools Related Companies Lifevantage Competitors I-Mab Competitors Black Diamond Therapeutics Competitors BioAge Labs Competitors Puma Biotechnology Competitors Nuvectis Pharma Competitors C4 Therapeutics Competitors Alpha Cognition Competitors Enanta Pharmaceuticals Competitors Molecular Partners Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CVM) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.